The neurointerventional radiologist at NYU Langone provided clarity on the individualized treatment options for cervical artery dissection following a scientific statement paper from the American Heart Association. [WATCH TIME: 7 minutes]
Adults with obstructive sleep apnea who receivied tirzepatide achieved an average of up to 20% weight loss and experienced at least 25 fewer breathing interruptions for each hour slept.
The director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]
The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
The assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]
The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]
The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Episode 29 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Allison Brashear MD, MBA, of University at Buffalo. [WATCH TIME: 5 minutes]
The head of Biogen’s MS and Immunology Department Unit detailed the potential of combination approaches to treat MS, including the reasons for diroximel fumarate in the newly initiated phase 2 FUSION study. [WATCH TIME: 3 minutes]
The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
Caution is warranted for older patients with Duchenne muscular dystrophy who are receiving gene therapy, according to details of a patient death in a single patient trial.
Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]
As therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.
The neurosurgeon in the department of neurology at Allegheny Health Network talked about the increasing prevalence of chronic pain as the population ages and the treatment options available to patients to provide relief. [WATCH TIME: 5 minutes]
A group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]
At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]
A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]
The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.
The chief executive at Encephalitis International talked about results from a recent survey conducted on the misconceptions of encephalitis recognition among emergency medical professionals. [WATCH TIME: 5 minutes]
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Psychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.
The president of the American Academy of Sleep Medicine emphasized the need to prioritize sleep for children and the organization’s efforts to improve sleep health.
The pediatric headache specialist at NYU Langone provided an inside perspective on the effect that societal stigmas have on those with pediatric migraine and how to address those stigmas.
Mary Meskis, executive director of the Dravet Syndrome Foundation, provided a opportunities the organization is offering in honor of Dravet Syndrome Awareness Month.
Episode 21 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Michael Dobbs, MD, MHCM, of University of Texas at Rio Grand Valley. [WATCH TIME: 5 minutes]